The global Major Histocompatibility Complex (MHC) Tetramer market was valued at US$ 11.9 million in 2024 and is anticipated to reach US$ 20.7 million by 2031, witnessing a CAGR of 8.2% during the forecast period 2025-2031.
An MHC tetramer is a laboratory tool used to study antigen-specific T cells. It consists of four major histocompatibility complex (MHC) molecules bound to a specific peptide and labeled with a fluorescent tag. These tetramers can bind to T cell receptors (TCRs) on the surface of T cells that recognize the specific peptide-MHC complex. By using flow cytometry, researchers can identify and quantify antigen-specific T cells, making MHC tetramers a valuable tool for immunological studies, including vaccine development, cancer immunotherapy, and infectious disease research.
In 2023, North America accounted for the largest sales share of the MHC tetramer market. The region is characterized by a large number of pharmaceutical R&D service providers. Meanwhile, Asia Pacific is expected to witness the highest CAGR during the forecast period.
The major global companies of Major Histocompatibility Complex (MHC) Tetramer include MBL Life Science, ProImmune, BioLegend, KACTUS, Creative Biolabs, immunAware, HELIXGEN, ACROBiosystems and etc. In 2023, the world's top three vendors accounted for approximately 56.50% of the revenue.
In terms of application, the continued research demand for cancer immunotherapy and adoptive T cell therapy and immune responses to emerging and re-emerging viral infectious diseases such as COVID-19, HIV and influenza is the main reason driving the MHC tetramer market. In 2023, MHC tetramers for cancer research accounted for approximately 48.00% of the market.
Currently, the MHC tetramer market mainly consists of two types: MHC-I and MHC-II. MHC-I is mainly used for research on cancer, viruses, bacteria, etc., and MHC-II is mainly used for research on viruses, bacteria, allergens, etc. In 2023, the sales of MHC-I and MHC-II will be US$6.63 million and US$4.29 million, respectively.
This report aims to provide a comprehensive presentation of the global market for Major Histocompatibility Complex (MHC) Tetramer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Major Histocompatibility Complex (MHC) Tetramer.
The Major Histocompatibility Complex (MHC) Tetramer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Major Histocompatibility Complex (MHC) Tetramer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Major Histocompatibility Complex (MHC) Tetramer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of Major Histocompatibility Complex (MHC) Tetramer manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of Major Histocompatibility Complex (MHC) Tetramer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
- ★ What Is The Overall Market Size And Projected Growth Rate Across Global And Regional Segments?
- ★ How Does The Market Size And Growth Outlook Vary Across Major Countries?
- ★ Which Region Or Market Sub-Segment Is Anticipated To Dominate Growth During The Forecast Period?
- ★ What Are The Primary Factors Expected To Drive Market Expansion, And What Challenges May Restrain Growth?
- ★ Which Emerging Technologies And Market Trends Are Shaping The Future Landscape?
- ★ What Are The Most Significant Opportunities Available In The Market?
- ★ Who Are The Leading Manufacturers Actively Participating In The Global Market?
- ★ Which Company Currently Holds The Largest Share Of The Market?
- ★ What Are The Potential Growth Avenues For New Entrants In The Global Market?